| Trial ID: | L2202 |
| Source ID: | NCT00793273
|
| Associated Drug: |
Insulin Detemir
|
| Title: |
Observational Study to Observe the Efficacy of Levemir® (Insulin Detemir) in Patients With Type 2 Diabetes.
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: insulin detemir
|
| Outcome Measures: |
Primary: Change in HbA1c of treatment, after 12 to 16 weeks|Change in FPG (fasting plasma glucose) of treatment, after 12 to 16 weeks | Secondary: Occurrence of adverse events, after 12 to 16 weeks|Insulin dose and concomitant oral antidiabetic medication time period between diagnosis of type 2 diabetes and insulin initiation, after 12 to 16 weeks
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
1074
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2008-11
|
| Completion Date: |
2011-01
|
| Results First Posted: |
|
| Last Update Posted: |
2014-08-15
|
| Locations: |
Zurich, Oerlikon, CH-8050, Switzerland
|
| URL: |
https://clinicaltrials.gov/show/NCT00793273
|
